Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nab-paclitaxel

Celgene building

Celgene’s triple multiple myeloma therapy clears phase III trial

The biotech says the combo hit its OPTIMISMM primary endpoint

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

Celgene building

Celgene reaches $9bn agreement to buy Juno

Acquires its blood cancer CAR-T candidate in the process

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

Celgene building

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Rumours circulate just days after the US biotech confirms ImpactBio purchase

Celgene building

Celgene boosts haematology pipeline with $7bn Impact Bio deal

Acquiring Sanofi’s rejected fedratinib candidate as part of the process

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links